MARC

LEADER 00000cam a2200000 a 4500
001 SCIDIR_ocn657415811
003 OCoLC
005 20231117044442.0
006 m o d
007 cr un||||a|a||
008 100823s1993 ne a ob 001 0 eng d
040 |a OCLCE  |b eng  |e pn  |c OCLCE  |d OCLCQ  |d OPELS  |d N$T  |d NLGGC  |d YDXCP  |d E7B  |d OCLCQ  |d UAB  |d OCLCO  |d OCLCA  |d OTZ  |d OCLCO  |d OCLCF  |d OCLCQ  |d STF  |d OCLCO  |d OCLCA  |d UKAHL  |d LUN  |d S2H  |d OCLCO  |d OCLCQ  |d OCLCO  |d COM  |d OCLCO  |d OCL  |d OCLCQ  |d OCLCO 
019 |a 621127710  |a 899003118  |a 974617479  |a 974671219  |a 987781904  |a 1100944076  |a 1257376784 
020 |a 9780444886552  |q (electronic bk.) 
020 |a 0444886559  |q (electronic bk.) 
020 |a 9781483164632  |q (electronic bk.) 
020 |a 1483164632  |q (electronic bk.) 
035 |a (OCoLC)657415811  |z (OCoLC)621127710  |z (OCoLC)899003118  |z (OCoLC)974617479  |z (OCoLC)974671219  |z (OCoLC)987781904  |z (OCoLC)1100944076  |z (OCoLC)1257376784 
042 |a dlr 
050 4 |a QP572.P4  |b D88 1993 
060 4 |a W1  |b PH272L v.19 1993 
060 4 |a WK 185  |b D979s 1993 
070 |a RS402.P42  |b v.19 
072 0 |a X300 
072 0 |a X380 
072 7 |a MED  |x 075000  |2 bisacsh 
072 7 |a SCI  |x 036000  |2 bisacsh 
082 0 4 |a 612/.015746  |2 20 
084 |a VK 8560  |2 rvk 
100 1 |a Dutta, A. S.  |q (Anand S.) 
245 1 0 |a Small peptides :  |b chemistry, biology, and clinical studies /  |c A.S. Dutta. 
260 |a Amsterdam ;  |a New York :  |b Elsevier,  |c 1993. 
300 |a 1 online resource (xvi, 616 pages) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Pharmacochemistry library ;  |v v. 19 
504 |a Includes bibliographical references and index. 
505 0 |a Angiotensin II -- Receptor subtypes of angiotensin II -- Agonist analogues of angiotensin II -- Peptide antagonists of angiotensin II -- Non-peptide antagonists of angiotensin II -- Non-peptide antagonists of angiotensin II acting at the AT₂ receptor -- Bombesin/gastrin-releasing peptide -- Antagonists of bombesin/GRP -- Conformationally restricted analogues of bombesin -- Bombesin/GRP antagonists and cancer -- Bradykinin analogues -- Receptor subtypes of bradykinin -- Agonist analogues of bradykinin -- Antagonists of bradykinin -- Biological profile of HOE 140 and related antagonists -- Side effects associated with bradykinin antagonists -- Cholecystokinin analogues -- Distribution and biological functions of cholecystokinin -- Cholecystokinin receptor subtypes and receptor-selective ligands -- Peptide antagonists of cholecystokinin and gastrin -- Non-peptide antagonists of CCK and gastrin -- Enkephalin analogues -- Enzymic inactivation of enkephalins -- Early structure activity relationship studies -- Agonist analogues displaying analgesic activity. 
505 0 |a (cont) Analogues with improved selectivity for the mu and delta receptors -- Antagonists of enkephalins -- Luteinising hormone releasing hormone -- Enzymic degradation of LHRH -- SAR of LHRH agonists -- SAR of LHRH antagonists -- LHRH antagonists and histamine release -- Hexapeptide derivatives as LHRH antagonists -- Ketaconazole derivatives as LHRH antagonists -- Formulations of LHRH and the analogues -- Pharmacological and clinical studies with LHRH agonists and antagonists -- Somatostatin -- Enzymatic degradation of somatostatin and analogues agonist analogues of somatostatin. SAR studies -- Clinical applications of somatostatin analogues -- Tachykinins -- Substance P, neurokinin A and neurokinin B -- Receptor subtypes of tachykinins -- SAR of the mammalian tachykinins -- Antagonists of substance P -- Antagonists of neurokinin A and neurokinin B -- Non-peptide antagonists of the tachykinins -- Biological studies using SP analogues -- Inhibitors of aspartyl proteases. 1.renin -- Inhibitors of renin -- Inhibitors of aspartyl proteases. 2. HIV protease. 
505 0 |a (cont) Nature of the enzyme -- Chemical approaches used in the design of inhibitors -- Non-peptide inhibitors of HIV protease -- Metallopeptidase (ace, enkephalinase and atriopeptidase) inhibitors -- Inhibitors of angiotensin converting enzyme -- Inhibitors of enkephalin degrading dipeptidyl-carboxypeptidase (enkephalinase) -- Inhibitors of atrial natriuretic factor (ANF) degrading enzyme -- Formulation of peptides -- Polymeric controlled drug delivery systems (depot formulations) -- Improvements in the oral delivery of peptides -- Intranasal administration of peptides -- Transdermal iontophoretic drug delivery of peptides -- Administration of peptides by ocular, vaginal and rectal routes. 
588 0 |a Print version record. 
506 |3 Use copy  |f Restrictions unspecified  |2 star  |5 MiAaHDL 
533 |a Electronic reproduction.  |b [Place of publication not identified] :  |c HathiTrust Digital Library,  |d 2010.  |5 MiAaHDL 
538 |a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.  |u http://purl.oclc.org/DLF/benchrepro0212  |5 MiAaHDL 
583 1 |a digitized  |c 2010  |h HathiTrust Digital Library  |l committed to preserve  |2 pda  |5 MiAaHDL 
650 0 |a Peptide hormones  |x Agonists. 
650 0 |a Peptide hormones  |x Antagonists. 
650 0 |a Neuropeptides  |x Agonists. 
650 0 |a Neuropeptides  |x Antagonists. 
650 0 |a Protein drugs. 
650 0 |a Hormones. 
650 2 |a Hormones  |0 (DNLM)D006728 
650 2 |a Peptides  |x antagonists & inhibitors  |0 (DNLM)D010455Q000037 
650 2 |a Neuropeptides  |x antagonists & inhibitors  |0 (DNLM)D009479Q000037 
650 2 |a Proteins  |x therapeutic use  |0 (DNLM)D011506Q000627 
650 2 |a Receptors, Peptide  |0 (DNLM)D018000 
650 6 |a Hormones peptidiques  |0 (CaQQLa)201-0023590  |x Agonistes.  |0 (CaQQLa)201-0374387 
650 6 |a Hormones peptidiques  |0 (CaQQLa)201-0023590  |x Antagonistes.  |0 (CaQQLa)201-0374866 
650 6 |a Neuropeptides  |0 (CaQQLa)201-0023738  |x Agonistes.  |0 (CaQQLa)201-0374387 
650 6 |a Neuropeptides  |0 (CaQQLa)201-0023738  |x Antagonistes.  |0 (CaQQLa)201-0374866 
650 6 |a M�edicaments prot�eiques.  |0 (CaQQLa)201-0249096 
650 6 |a Hormones.  |0 (CaQQLa)201-0017163 
650 7 |a hormone.  |2 aat  |0 (CStmoGRI)aat300265405 
650 7 |a MEDICAL  |x Physiology.  |2 bisacsh 
650 7 |a SCIENCE  |x Life Sciences  |x Human Anatomy & Physiology.  |2 bisacsh 
650 7 |a Hormones  |2 fast  |0 (OCoLC)fst00960219 
650 7 |a Protein drugs  |2 fast  |0 (OCoLC)fst01079679 
650 7 |a Antagonist  |2 gnd  |0 (DE-588)4198647-7 
650 7 |a Arzneimittel  |2 gnd  |0 (DE-588)4003115-9 
650 7 |a Neuropeptide  |2 gnd  |0 (DE-588)4041895-9 
650 7 |a Peptide  |2 gnd  |0 (DE-588)4045125-2 
650 7 |a Peptidhormon  |2 gnd  |0 (DE-588)4045127-6 
653 0 |a Peptides 
776 0 8 |i Print version:  |a Dutta, A.S. (Anand S.).  |t Small peptides.  |d Amsterdam ; New York : Elsevier, 1993  |w (DLC) 93011629  |w (OCoLC)28498594 
830 0 |a Pharmacochemistry library ;  |v v. 19. 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/book/9780444886552  |z Texto completo 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/bookseries/01657208/19  |z Texto completo